摘要异基因造血干细胞移植(allo-HSCT)是唯一可能治愈多发性骨髓瘤(MM)的方法,但较高的移植相关死亡(TRM)率限制了其应用.尽管减低强度预处理(RIC)的allo-HSCT降低了TRM率,但其疗效仍不优于自体造血干细胞移植(auto-HSCT).因此需要进一步研究降低移植毒性和促进移植物抗骨髓瘤(GVM)效应的新策略,以便使RIC allo-HSCT更加安全有效.文章对目前allo-HSCT在MM中的研究进展进行了综述.

abstractsAllogeneic stem cell transplantation (allo-HSCT) is probably the only treatment for multiple myeloma (MM) with a curative potential.However,the application of allo-HSCT is limited by the high transplant-related mortality (TRM).Although the introduction of reduced intensity conditioning (RIC) has lowered the TRM associated with myeloablative conditioning,there is no improvement in survival of allo-RIC compared to autologous stem cell transplantation (auto-HSCT).New strategies are discussed with the aim of lowering transplant toxicity and boosting the graft-versus-myeloma effect,and these are urgently needed to make allo-RIC safer and more effective for myeloma patients.In this review,results from studies of allo-HSCT in MM are presented.